"We have recently received final approval for rifapentine from the
Indian regulatory authorities. Rifapentine is now officially
registered in India," Thibaud Lefort, Sanofi's global health business
chief, told ET on the sidelines of the 50th Union World Conference of
Lung Health in Hyderabad.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/regulator-waives-off-clinical-trials-clears-sanofi-tb-drug/articleshow/71931597.cms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment